LBB Specialties Enters into Strategic Partnership for Excipient Product Distribution

News
Article

LBB Specialties and Meggle Excipients & Technology will work to distribute excipient products to companies in the American pharmaceutical and nutraceutical industries.

LeBaronBrown Specialties (LBB), a North American specialty chemical and ingredients distribution company, announced it entered into a strategic partnership on Aug. 1, 2019 with Meggle Excipients & Technology, a Wasserburg, Germany-based holding company in the dairy industry, to distribute its excipient products to companies in the American pharmaceutical and nutraceutical industries. 

American International Chemical (AIC) and Charkit Chemical Company, LBB Specialties’ subsidiary companies, will handle the sales, marketing, and distribution efforts for Meggle products in the US market, according to an Aug. 27, 2019 press release. 

Meggle provides the pharmaceutical industry with lactose-based excipients for direct compression and granulation tableting, powder preparations, and dry powder inhalation while investing sufficiently in R&D.

“Representing [Meggle] is a tremendous addition for Charkit and AIC,” said Jay Lang, president of Charkit Chemical, in the press release. “[Meggle] is one of only a handful of manufacturers of pharma-grade lactose excipients in the world, and they are well known for the excellent quality of their product portfolio, including value-added excipients for direct compression and inhalation applications.”

“The industry knowledge, customer focus, and broad-based capabilities offered by Charkit and AIC make them excellent partners for [Meggle],” said Ruth Leinenbach, director, BG Excipients and Technology at Meggle, in the press release. “The combination of our technical knowledge and the professional sales expertise of our new partners is a powerful recipe for success.”

Source: LBB Specialties 

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content